2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Polycystic Ovary Syndrome
152
Breast Neoplasms
40
Prostatic Neoplasms
31
Insulin Resistance
30
Obesity
23
Neoplasms
15
Endometrial Neoplasms
15
Pancreatic Neoplasms
14
Infertility
14
Colorectal Neoplasms
13
Carcinoma, Non-Small-Cell Lung
12
Anovulation
10
Lung Neoplasms
9
Neoplasm Metastasis
8
Hyperandrogenism
8
Glioblastoma
8
Diabetes Mellitus
8
Squamous Cell Carcinoma of Head and Neck
7
Metabolic Syndrome
7
Melanoma
7
Rectal Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Ovarian Neoplasms
5
Lymphoma, Large B-Cell, Diffuse
5
Head and Neck Neoplasms
5
Brain Neoplasms
5
Adenocarcinoma
5
Weight Loss
4
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Interventions
Fulvestrant
10
Alpelisib
7
Everolimus
6
Cetuximab
6
Letrozole
4
serabelisib
3
ribociclib
3
pembrolizumab
3
palbociclib
3
duvelisib
3
berzosertib
3
Paclitaxel
3
PX-866
3
NVP-BKM120
3
Irinotecan
3
sapanisertib
2
parsaclisib
2
olaparib
2
binimetinib
2
Topotecan
2
Gemcitabine
2
Carboplatin
2
volagidemab
1
venetoclax
1
tivozanib
1
tipifarnib
1
tanezumab
1
talazoparib
1
sotorasib
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Metformin
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled